SEC 13F Intelligence

Cambridge Investment Research Advisors, Inc. / LLY

Cambridge Investment Research Advisors, Inc.’s Eli Lilly & Co Position

Does Cambridge Investment Research Advisors, Inc. own Eli Lilly & Co (LLY)? Yes — 173.5K shares worth $160M (+0.41% of its 13F portfolio) as of Q1 2026, down from 174.0K shares the prior filed quarter.

Position Value
$160M
Q1 2026
Shares
173.5K
% of Portfolio
+0.41%
Quarters Held
30
currently held

Position History LLY

Reported value by quarter
Q4 ’18: $18MQ4 ’18Q1 ’19: $13MQ2 ’19: $11MQ3 ’19: $11MQ4 ’19: $14MQ4 ’19Q1 ’20: $13MQ2 ’20: $16MQ3 ’20: $16MQ4 ’20: $17MQ4 ’20Q1 ’21: $20MQ2 ’21: $24MQ3 ’21: $24MQ4 ’21: $30MQ4 ’21Q1 ’22: $36MQ2 ’22: $41MQ3 ’22: $45MQ4 ’22: $53MQ4 ’22Q1 ’23: $52MQ2 ’23: $81MQ3 ’23: $89MQ4 ’23: $94MQ4 ’23Q1 ’24: $129MQ2 ’24: $152MQ3 ’24: $146MQ4 ’24: $123MQ4 ’24Q1 ’25: $135MQ2 ’25: $132MQ3 ’25: $135MQ4 ’25: $187MQ4 ’25Q1 ’26: $160Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026173.5K$160M+0.41%
Q4 2025174.0K$187M+0.49%
Q3 2025176.8K$135M+0.37%
Q2 2025169.6K$132M+0.40%
Q1 2025163.2K$135M+0.45%
Q4 2024159.2K$123M+0.41%
Q3 2024164.8K$146M+0.50%
Q2 2024167.9K$152M+0.56%
Q1 2024165.4K$129M+0.50%
Q4 2023161.9K$94M+0.40%
Q3 2023165.7K$89M+0.42%
Q2 2023173.4K$81M+0.37%
Q1 2023152.8K$52M+0.26%
Q4 2022144.7K$53M+0.27%
Q3 2022137.7K$45M+0.25%
Q2 2022125.9K$41M+0.22%
Q1 2022127.0K$36M+0.17%
Q4 2021106.9K$30M+0.13%
Q3 2021101.8K$24M+0.12%
Q2 2021103.5K$24M+0.11%
Q1 2021107.3K$20M+0.11%
Q4 2020103.3K$17M+0.10%
Q3 2020105.8K$16M+0.11%
Q2 2020100.4K$16M+0.12%
Q1 202097.3K$13M+0.13%
Q4 2019102.9K$14M+0.10%
Q3 2019100.2K$11M+0.10%
Q2 2019102.3K$11M+0.10%
Q1 2019103.2K$13M+0.13%
Q4 2018152.6K$18M+0.20%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Cambridge Investment Research Advisors, Inc.’s full portfolio or all institutional holders of LLY.